Your browser doesn't support javascript.
loading
Feasibility of a preventive HIV-1 vaccine cohort among persons attending sexually transmitted disease clinics in Thailand.
Markowitz, L E; Sirisopana, N; Charonwatanachokchai, A; Julvanichpong, W; Siraprapasiri, T; Palanuvej, T; Siriwongrangsun, P; Tungsakul, V; Pumratana, K; Chitwarakorn, A; Michael, R A; Brown, A E.
Afiliación
  • Markowitz LE; Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. lem2@cdc.gov
J Acquir Immune Defic Syndr Hum Retrovirol ; 20(5): 488-94, 1999 Apr 15.
Article en En | MEDLINE | ID: mdl-10225232
ABSTRACT
PIP: Thailand is one of the few countries in which plans for HIV-1 vaccine efficacy trials are proceeding. The determination of cohort sample size for such trials depends upon the HIV-1 incidence among those who may enroll in the trials, participant retention, trial duration, and the frequency of risk behavior during the trial. The authors conducted a prospective cohort study of sexually transmitted disease (STD) clinic attendees at 3 sites in Thailand to determine whether a cohort in the population would be suitable for future HIV-1 vaccine efficacy trials. Between September 1995 and February 1996, 371 of 1205 (31%) eligible men and 161 of 659 (24%) eligible women agreed to participate in a 1-year study of HIV-1 incidence. At enrollment, 3.8% of the men and 2.5% of the women were infected with HIV-1. Almost all women and 54% of the men were married at the time of enrollment. 78% of the 514 participants who were seronegative at baseline were still being followed at the 12-month visit. During the study period, 53% of men reported having 2 or more sex partners, 31% reported having sex with a prostitute, and 33% with a casual partner. 72% of those frequenting prostitutes reported consistent condom use. 11% of women reported 2 or more sex partners. Decreased HIV risk behaviors among men were observed during the study. 4 incident infections occurred in men and none among the women. Based upon this observed HIV-1 infection incidence, HIV vaccine efficacy trials in such populations would have to be larger than previously planned or more selective of high-risk subgroups for recruitment.
Asunto(s)
Palabras clave
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Vacunas contra el SIDA Tipo de estudio: Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: J Acquir Immune Defic Syndr Hum Retrovirol Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) / VIROLOGIA Año: 1999 Tipo del documento: Article País de afiliación: Tailandia Pais de publicación: Estados Unidos
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Vacunas contra el SIDA Tipo de estudio: Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: J Acquir Immune Defic Syndr Hum Retrovirol Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) / VIROLOGIA Año: 1999 Tipo del documento: Article País de afiliación: Tailandia Pais de publicación: Estados Unidos